Skip to main content

Deltagen Appoints interim CEO; ChrondoGene Adds Member to SAB; and Others

NEW YORK, April 4 -- Joseph Limber has been appointed interim CEO of Deltagen, the company said today, and will move on to be president and CEO as soon as Deltagen closes an equity financing.


Limber was president and CEO of Aclara BioSciences until 2002. Prior to that, he was president and COO at Praecis Pharmaceuticals. He also held senior business development and sales and marketing positions with Sequus Pharmaceuticals, Syntex, and Ciba-Geigy.

Frank Barry has been appointed to the scientific advisory board of ChondroGene, the company said today.


Barry is the director for arthritis research at Osiris Therapeutics. He has held teaching positions at a variety of institutions, including the University College Cork, the University of South Florida College of Medicine, and JohnsHopkinsUniversity.

Jim Bull has become head of North American sales of New Milton, UK-based Genetix Group, the company said March 31.


Most recently, Bull was director of sales at GeneMachines. Prior to that, he held sales and marketing positions at Molecular Dynamics, later Amersham Pharmacia Biotech, including those of product manager and director of North American sales.

Baron Frederick Charles von Nidda has been named general manager of Applied DNA Sciences, the company said March 31.


Von Nidda, a partner in the European-advisory firm GA Associates, has recently helped with the finance and expansion of a number of independent businesses, including the engineering firm Minimould, the pharma company Res-Del International, the medical firm Clinical Research Centres International; and the media concern Tri-Continental Films.

The UK Biobank has appointed John Newton as CEO.


Newtonhas been the consultant epidemiologist at the Department of Public Health and Primary Care at Oxfordfor eleven years, and was also director of R&D at the Oxford Radcliffe Hospitals NHS Trust.

Brian Ritchie, formerly CEO and president of Blackstone Computing (most recently Argentys) has joined storage consulting services firm GlassHouse Technologies as senior vice president of sales.



The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.